Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Slides:

Advertisements

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Advertisements

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels Michael H. Davidson, MD Journal of Clinical.

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli.

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial Erik S.G. Stroes, MD, PhD, Andrey.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

% decrease in LDL-C at 24 weeks from baseline

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia Joep C. Defesche, PhD,

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia Aurélie.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis Robert Wolk, MD, PhD, DSc, Ehrin J.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo- controlled study Patrick M. Moriarty, MD, Eli M. Roth, MD, Adam.

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized.

Genetic epidemiology of autosomal recessive hypercholesterolemia in Sicily: Identification by next-generation sequencing of a new kindred Rossella Spina,

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol,

Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia? Joana Rita Chora, MSc, Ana Catarina Alves, PhD, Ana.

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

An assessment by the Statin Intolerance Panel: 2014 update

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment.

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia G. Kees Hovingh, MD,

Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment Robert Dufour,

Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients Alberto Zamora,

Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical.

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT.

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

Urbanization, mainly rurality, but not altitude is associated with dyslipidemia profiles Maria Lazo-Porras, Antonio Bernabe-Ortiz, Renato Quispe, German.

III. Treating dyslipidemias

Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia Frederick J. Raal, PhD, Marjet J. Braamskamp,

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design Dirk J. Blom, MD, PhD, Zahi A. Fayad,

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

Presentation transcript:

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial Robert Dufour, MD, MSc, CSPQ, G. Kees Hovingh, MD, PhD, MBA, John R. Guyton, MD, Gisle Langslet, MD, Marie T. Baccara-Dinet, MD, MSc, Chantal Din-Bell, MSc, Garen Manvelian, MD, Michel Farnier, MD, PhD Journal of Clinical Lipidology Volume 13, Issue 1, Pages 138-147 (January 2019) DOI: 10.1016/j.jacl.2018.11.007 Copyright © 2018 National Lipid Association Terms and Conditions

Figure 1 OLE study design. aPatients receiving placebo were part of the OLE study but were not included in this analysis. bPosttreatment follow-up call to be performed 10 weeks after the last injection. HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III; OLE, open-label extension; Q2W, every 2 weeks; TLC, therapeutic lifestyle changes; W, week. Journal of Clinical Lipidology 2019 13, 138-147DOI: (10.1016/j.jacl.2018.11.007) Copyright © 2018 National Lipid Association Terms and Conditions

Figure 2 Percent LDL-C change from baseline to Week 8 in the LONG TERM parent study and the OLE study, in the same cohort of HeFH patients (mITT analysis)a. aOnly patients who have all 4 LDL-C measurements (parent study baseline, OLE baseline, Week 8 parent study, and Week 8 OLE study) are included in this analysis. bResults for patient cohort during the LONG TERM study (n = 179). cResults for patient cohort during the OLE study (n = 179). LDL-C, low-density lipoprotein cholesterol; Q2W, every 2 weeks; mITT, modified intent-to-treat; SD, standard deviation; SE, standard error. Journal of Clinical Lipidology 2019 13, 138-147DOI: (10.1016/j.jacl.2018.11.007) Copyright © 2018 National Lipid Association Terms and Conditions

Figure 3 Percent change in (A) HDL-C, (B) non-HDL-C, (C) TC, and (D) TGs from baseline to Week 8 in the LONG TERM parent study and OLE study, in the same cohort of HeFH patients (mITT analysis). Patient numbers for each lipid parameter are as follows: HDL-C, non-HDL-C, and TC, n = 185; TGs, and n = 182 respectively. aResults for patient cohort during the LONG TERM study. bResults for patient cohort during the OLE study. HDL-C, high-density lipoprotein cholesterol; mITT, modified intention-to-treat; Q2W, every 2 weeks; SD, standard deviation; SE, standard error; TC, total cholesterol; TGs, triglycerides. Journal of Clinical Lipidology 2019 13, 138-147DOI: (10.1016/j.jacl.2018.11.007) Copyright © 2018 National Lipid Association Terms and Conditions

Figure 4 Mean (SD) LDL-C levels over time according to alirocumab dose increase status in OLE (mITT analysis). LDL-C, low-density lipoprotein cholesterol; mITT, modified intention-to-treat; Q2W, every 2 weeks; SD, standard deviation. Journal of Clinical Lipidology 2019 13, 138-147DOI: (10.1016/j.jacl.2018.11.007) Copyright © 2018 National Lipid Association Terms and Conditions